REGENERON PHARMACEUTICALS, INC. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
REGENERON PHARMACEUTICALS, INC. (REGN) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $401.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $401.90M, a 13.69% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $353.50M, a 130.44% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $153.40M, a 12.05% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $136.90M, a 24.90% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month as first filed |
|---|---|---|
| 2025-12-31 | $401.90M 10-K · filed 2026-02-04 | |
| 2024-12-31 | $353.50M 10-K · filed 2026-02-04 | |
| 2023-12-31 | $153.40M 10-K · filed 2026-02-04 | |
| 2022-12-31 | $136.90M 10-K · filed 2025-02-05 | |
| 2021-12-31 | $182.30M 10-K · filed 2024-02-05 | |
| 2020-12-31 | $76.60M 10-K · filed 2023-02-06 | |
| 2019-12-31 | $37.90M 10-K · filed 2022-02-07 | |
| 2018-12-31 | $51.40M 10-K · filed 2021-02-08 | |
| 2017-12-31 | $49.00M 10-K · filed 2020-02-07 | $49.03M 10-K · filed 2018-02-08 |
| 2016-12-31 | $45.60M 10-K · filed 2019-02-07 | $45.58M 10-K · filed 2017-02-09 |
| 2015-12-31 | $59.91M 10-K · filed 2018-02-08 | |
| 2014-12-31 | $27.54M 10-K · filed 2017-02-09 | |
| 2013-12-31 | $7.62M 10-K · filed 2016-02-11 | |
| 2012-12-31 | $1.87M 10-K · filed 2015-02-12 | |
| 2011-12-31 | $2.19M 10-K · filed 2014-02-13 | |
| 2010-12-31 | $3.55M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |